Cellgevity® supplement stalls diabetic renal dysfunction in male rats

Abstract

Chronic excessive ROS formation instigates oxidative stress, inflammation and the inhibition of vital physiological processes, including renal Na⁺/K⁺-ATPase activity, thereby facilitating the progression of diabetic kidney damage. This study investigated the therapeutic impact of Cellgevity® (a poly-antioxidant supplement) against streptotozin-induced diabetic kidney dysfunction in male rats. Twenty-eight matured male rats randomised into – Control group, Diabetes-Untreated, Diabetes-Treated 1 and Diabetes-Treated 2 groups. Daily oral treatment of the Diabetes-Treated groups with therapeutic doses of Cellgevity® suspension in distilled water (25 mg/kg and 40 mg/kg BW respectively) was conducted for 30 days, while the control and Diabetic-Untreated groups received distilled water (placebo). Results show that Cellgevity® reduced kidney lipid peroxidation, prevented kidney enlargement and renal TNF-α and nitrite accumulation, and increased renal Na⁺/K⁺-ATPase activity compared to the untreated diabetic group. The Cellgevity® treatment also increased the actions of renal glutathione peroxidase, superoxide dismutase, and catalase by at least 70% compared to the untreated diabetic group. The serum levels of creatinine, blood urea nitrogen, HCO₃, Na⁺ and K⁺ of the treated diabetic groups were also significantly normalised to the levels of the control group. The results demonstrate the anti-oxidative-nitrosative and anti-inflammation impact of Cellgevity® against diabetic renal dysfunction. The result presents a good incentive for anti-oxidant supplements in the management of diabetes and its complications.